E
Cardiol Therapeutics Inc.
CRDL
$1.17
$0.0857.87%
E
Sell
12/20/2024Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 12/20/2024 due to a major decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0701 to -$0.1336, EBIT declined 83.26% from -$5.66M to -$10.37M, and operating cash flow declined 63.21% from -$3.49M to -$5.7M.
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 12/20/2024 due to a major decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0701 to -$0.1336, EBIT declined 83.26% from -$5.66M to -$10.37M, and operating cash flow declined 63.21% from -$3.49M to -$5.7M.
D
Sell
2/8/2024Upgraded
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 2/8/2024 due to an increase in the total return index and volatility index.
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 2/8/2024 due to an increase in the total return index and volatility index.
E
Sell
1/24/2024Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 1/24/2024 due to a decline in the volatility index and valuation index.
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 1/24/2024 due to a decline in the volatility index and valuation index.
D
Sell
1/4/2024Upgraded
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index.
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index.
E
Sell
12/15/2023Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 12/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 5.37 to 5.08.
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 12/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 5.37 to 5.08.
D
Sell
7/20/2023Upgraded
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 7/20/2023 due to an increase in the volatility index and total return index.
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 7/20/2023 due to an increase in the volatility index and total return index.
E
Sell
7/5/2023Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 7/5/2023 due to a decline in the volatility index.
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 7/5/2023 due to a decline in the volatility index.
D
Sell
6/15/2023Upgraded
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 6/15/2023 due to an increase in the growth index, total return index and volatility index. EBIT increased 14.09% from -$6.7M to -$5.76M, and earnings per share increased from -$0.0867 to -$0.0818.
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 6/15/2023 due to an increase in the growth index, total return index and volatility index. EBIT increased 14.09% from -$6.7M to -$5.76M, and earnings per share increased from -$0.0867 to -$0.0818.
E
Sell
3/14/2023Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 03/14/2023.
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
Cardiol Therapeutics Inc. (CRDL) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index, growth index and volatility index. EBIT declined 40.1% from -$7.23M to -$10.13M, earnings per share declined from -$0.0821 to -$0.098, and operating cash flow declined 9.55% from -$3.43M to -$3.75M.
Cardiol Therapeutics Inc. (CRDL) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index, growth index and volatility index. EBIT declined 40.1% from -$7.23M to -$10.13M, earnings per share declined from -$0.0821 to -$0.098, and operating cash flow declined 9.55% from -$3.43M to -$3.75M.
D
Sell
11/10/2022Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to D- from D on 11/10/2022 due to a decline in the volatility index.
Cardiol Therapeutics Inc. (CRDL) was downgraded to D- from D on 11/10/2022 due to a decline in the volatility index.
D
Sell
8/15/2022Upgraded
Cardiol Therapeutics Inc. (CRDL) was upgraded to D from D- on 8/15/2022 due to a major increase in the growth index and valuation index. Operating cash flow increased 51.89% from -$7.13M to -$3.43M, earnings per share increased from -$0.1142 to -$0.0821, and EBIT increased 6.37% from -$7.73M to -$7.24M.
Cardiol Therapeutics Inc. (CRDL) was upgraded to D from D- on 8/15/2022 due to a major increase in the growth index and valuation index. Operating cash flow increased 51.89% from -$7.13M to -$3.43M, earnings per share increased from -$0.1142 to -$0.0821, and EBIT increased 6.37% from -$7.73M to -$7.24M.
D
Sell
1/26/2022Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to D- from D on 1/26/2022 due to a large decline in the total return index and volatility index.
Cardiol Therapeutics Inc. (CRDL) was downgraded to D- from D on 1/26/2022 due to a large decline in the total return index and volatility index.
D
Sell
11/16/2021Upgraded
Cardiol Therapeutics Inc. (CRDL) was upgraded to D from D- on 11/16/2021 due to an increase in the valuation index.
Cardiol Therapeutics Inc. (CRDL) was upgraded to D from D- on 11/16/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Cardiol Therapeutics Inc. (CRDL) was downgraded to D- from D on 11/08/2021.
Cardiol Therapeutics Inc. (CRDL) was downgraded to D- from D on 11/08/2021.
D
Sell
8/13/2021Upgraded
Cardiol Therapeutics Inc. (CRDL) was upgraded to D from D- on 8/13/2021 due to an increase in the total return index.
Cardiol Therapeutics Inc. (CRDL) was upgraded to D from D- on 8/13/2021 due to an increase in the total return index.
D
Sell
7/29/2021Downgrade
Cardiol Therapeutics Inc. (CRTPF) was downgraded to D- from D on 7/29/2021 due to a decline in the volatility index, growth index and solvency index. Operating cash flow declined 181.77% from -$1.99M to -$5.6M.
Cardiol Therapeutics Inc. (CRTPF) was downgraded to D- from D on 7/29/2021 due to a decline in the volatility index, growth index and solvency index. Operating cash flow declined 181.77% from -$1.99M to -$5.6M.
D
Sell
3/22/2021Upgraded
Cardiol Therapeutics Inc. (CRTPF) was upgraded to D from D- on 3/22/2021 due to an increase in the volatility index and total return index.
Cardiol Therapeutics Inc. (CRTPF) was upgraded to D from D- on 3/22/2021 due to an increase in the volatility index and total return index.
D
Sell
11/16/2020Downgrade
Cardiol Therapeutics Inc. (CRTPF) was downgraded to D- from D on 11/16/2020 due to a major decline in the growth index and volatility index. Operating cash flow declined 161.75% from -$855.4 to -$2.24M, EBIT declined 22.81% from -$2.39M to -$2.93M, and earnings per share declined from -$0.0939 to -$0.1008.
Cardiol Therapeutics Inc. (CRTPF) was downgraded to D- from D on 11/16/2020 due to a major decline in the growth index and volatility index. Operating cash flow declined 161.75% from -$855.4 to -$2.24M, EBIT declined 22.81% from -$2.39M to -$2.93M, and earnings per share declined from -$0.0939 to -$0.1008.
D
Sell
5/20/2020Upgraded
Cardiol Therapeutics Inc. (CRTPF) was upgraded to D from D- on 5/20/2020 due to a large increase in the growth index. Operating cash flow increased 21.97% from -$2.32M to -$1.81M, EBIT increased 15.6% from -$2.28M to -$1.92M, and earnings per share increased from -$0.0895 to -$0.0848.
Cardiol Therapeutics Inc. (CRTPF) was upgraded to D from D- on 5/20/2020 due to a large increase in the growth index. Operating cash flow increased 21.97% from -$2.32M to -$1.81M, EBIT increased 15.6% from -$2.28M to -$1.92M, and earnings per share increased from -$0.0895 to -$0.0848.
D
Sell
3/4/2020Upgraded
Cardiol Therapeutics Inc. (CRTPF) was upgraded to D- from E+ on 3/4/2020 due to an increase in the volatility index and valuation index.
Cardiol Therapeutics Inc. (CRTPF) was upgraded to D- from E+ on 3/4/2020 due to an increase in the volatility index and valuation index.
E
Sell
2/18/2020Downgrade
Cardiol Therapeutics Inc. (CRTPF) was downgraded to E+ from D- on 2/18/2020 due to a decline in the volatility index, valuation index and solvency index. The quick ratio declined from 16.22 to 7.08.
Cardiol Therapeutics Inc. (CRTPF) was downgraded to E+ from D- on 2/18/2020 due to a decline in the volatility index, valuation index and solvency index. The quick ratio declined from 16.22 to 7.08.
D
Sell
10/1/2019Upgraded
Cardiol Therapeutics Inc. (CRTPF) was upgraded to D- from E on 10/1/2019 due to an increase in the valuation index.
Cardiol Therapeutics Inc. (CRTPF) was upgraded to D- from E on 10/1/2019 due to an increase in the valuation index.
E
Sell
7/1/2019Upgraded
Cardiol Therapeutics Inc. (CRTPF) was upgraded to E from E- on 7/1/2019 due to an increase in the growth index.
Cardiol Therapeutics Inc. (CRTPF) was upgraded to E from E- on 7/1/2019 due to an increase in the growth index.
E
Sell
5/15/2019Downgrade
Cardiol Therapeutics Inc. (CRTPF) was downgraded to E- from E on 5/15/2019 due to a major decline in the volatility index and efficiency index. Total capital declined 0.65% from $16.52M to $16.41M.
Cardiol Therapeutics Inc. (CRTPF) was downgraded to E- from E on 5/15/2019 due to a major decline in the volatility index and efficiency index. Total capital declined 0.65% from $16.52M to $16.41M.
E
Sell
4/10/2019None
Cardiol Therapeutics Inc. (CRDL) was downgraded to E from U on 04/10/2019.
Cardiol Therapeutics Inc. (CRDL) was downgraded to E from U on 04/10/2019.
NASDAQ
03/07/2025 3:59PM Eastern
Quotes delayed
